Tacrolimus (or cyclosporine)

DRUG2 trials

Sponsors

University of Michigan Rogel Cancer Center, M.D. Anderson Cancer Center

Conditions

Acute Leukemia in RemissionChronic Myelogenous Leukemia - Chronic PhaseChronic Myelogenous Leukemia, Accelerated PhaseChronic Myelogenous Leukemia, Blastic PhaseDiffuse Large B Cell LymphomaFollicular LymphomaGraft Vs Host DiseaseGraft-versus-host-disease

Phase 1

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Active, not recruitingNCT03842696

University of Michigan Rogel Cancer CenterAcute Leukemia in Remission, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase +9

Start: 2020-02-04End: 2026-04-01Updated: 2026-01-27

Phase 2

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

WithdrawnNCT05293509

M.D. Anderson Cancer CenterStem Cell Transplantation

Start: 2022-03-02End: 2023-09-18Updated: 2023-09-21

Related Papers

Cognitive Functioning in Vorinostat-Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant.

2026-03-23

Vorinostat for GVHD prophylaxis in children, adolescents, and young adults (AYA) shows low incidence of acute GVHD and relapse with encouraging overall survival after allogeneic hematopoietic cell transplantation (HCT): A multisite, nonrandomized clinical trial

Blood2025-11-03